Cullinan Management (CGEM) AI Stock Analysis

• Market Cap: $816.50M
• Dividend Yield: N/A
• Average Volume (3M): 792.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: N/A
• EPS Growth: -27.86%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.77
• Shares Outstanding: 60,526,127
• 10 Day Avg. Volume: 799,834
• 30 Day Avg. Volume: 792,710
• PEG Ratio: -0.14
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.48
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.59K
• Enterprise Value/Ebitda: -2.94
• 1Y Price Target: $29.69
• Price Target Upside: 120.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): -3.07
• Revenue Forecast (FY): $23.98M

• Rating: 59 Neutral
• Price Target: $16.00 ▲(18.61% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

Score is held back primarily by weak financial performance (minimal revenue, widening losses, and heavy cash burn), partially offset by a low-debt balance sheet. Technicals are constructive with strong multi-timeframe uptrend and positive momentum indicators, while valuation remains difficult to assess due to negative earnings. A recent corporate update adds upside potential via a catalyst-rich 2026 pipeline and stated runway into 2029.

Positive Factors

Strong cash runway

A ~$439M liquidity buffer and stated runway into 2029 materially reduces near-term financing risk and permits execution of multi-year clinical programs. This durable cash cushion gives management time to reach 2026 value inflection points before needing large external capital raises.

Catalyst-rich, diversified pipeline

A multi-program T cell engager pipeline across autoimmune and oncology with several 2026 readouts creates multiple, staggered value drivers. Diversification across indications reduces binary program risk and increases odds of at least one clinical or regulatory success that can transform long-term commercial prospects.

Partnerships and regulatory progress

Regulatory designations and a strategic partner provide non-dilutive resources, regulatory support, and potential milestone/profit-share economics. Fast Track can accelerate development while Taiho’s rolling NDA and milestone structure offer commercialization scale and downside protection versus going it alone.

Negative Factors

Minimal revenue and widening losses

The company remains pre-commercial with effectively no recurring revenue and materially widening net losses over recent years. Persistent operating losses reflect development-stage economics and mean long-term shareholder value depends entirely on successful clinical/regulatory outcomes rather than current cash generation.

Deepening cash burn

Rising negative operating and free cash flow indicates increasing funding needs to sustain clinical programs. Even with current runway, persistent burn can force reprioritization of programs, accelerated dilution, or dependence on partner deals, which can reshape long-term strategy and upside for shareholders.

Eroding balance-sheet buffer

Significant declines in assets and equity over a single year show cash burn is depleting the company’s financial cushion. This reduces flexibility for unexpected trial costs or launch expenses and increases the probability that future financing will be required on potentially dilutive terms if clinical timelines slip.

Cullinan Management Business Overview & Revenue Model

Company Description

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

How the Company Makes Money

Cullinan Management Financial Statement Overview

Summary

Financial profile remains weak: minimal revenue, widening net losses (about -$153M in 2023 to about -$220M in 2025), and deepening operating/free cash flow burn (about -$176M FCF in 2025). The main offset is low leverage (about $2.7M debt vs. about $408.7M equity in 2025), though assets and equity declined from 2024 to 2025, underscoring ongoing runway/funding risk.

Income Statement

Operating performance is weak and volatile, consistent with a development-stage pharma profile. Revenue is effectively zero in most years (only a modest $18.9M in 2021), while losses are sizable and widening recently (net loss of ~$153.2M in 2023, ~$167.4M in 2024, and ~$219.9M in 2025). Profitability is therefore poor with negative operating results across the last three years, and the business has not yet shown a clear path to recurring revenue.

Balance Sheet

The balance sheet is a relative strength due to very low leverage: total debt is minimal (~$2.7M in 2025) versus a sizable equity base (~$408.7M in 2025), implying limited balance-sheet debt risk. That said, equity and total assets have declined from 2024 to 2025 (equity ~$590.3M to ~$408.7M; assets ~$621.8M to ~$448.4M), reflecting ongoing cash burn and losses, which can pressure future financial flexibility if sustained.

Cash Flow

Cash generation is weak with consistently negative operating cash flow and free cash flow, and the burn rate is increasing in the most recent period (operating cash flow about -$134.3M in 2023, -$145.3M in 2024, and -$175.8M in 2025; free cash flow about -$175.8M in 2025). While 2025 shows a positive free cash flow growth figure, absolute cash flow remains deeply negative, indicating continued reliance on external funding or existing cash reserves.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	18.94M
Gross Profit	-311.00K	-306.00K	-310.00K	0.00	18.94M
EBITDA	-241.65M	-167.15M	-190.34M	-132.04M	-67.90M
Net Income	-219.88M	-167.38M	-153.16M	111.21M	-65.57M
Balance Sheet
Total Assets	448.37M	621.82M	484.18M	561.12M	437.19M
Cash, Cash Equivalents and Short-Term Investments	377.90M	398.98M	467.07M	467.29M	290.47M
Total Debt	2.68M	2.15M	3.59M	5.19M	0.00
Total Liabilities	39.64M	31.50M	30.29M	26.09M	11.81M
Stockholders Equity	408.73M	590.33M	453.70M	535.03M	424.97M
Cash Flow
Free Cash Flow	-175.80M	-145.30M	-134.48M	-127.80M	-44.02M
Operating Cash Flow	-175.75M	-145.30M	-134.28M	-126.66M	-43.43M
Investing Cash Flow	179.99M	-136.31M	35.81M	248.97M	-333.77M
Financing Cash Flow	1.09M	266.19M	40.75M	-25.93M	268.78M

Cullinan Management Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.49
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEM, the sentiment is Neutral. The current price of 13.49 is below the 20-day moving average (MA) of 14.42, above the 50-day MA of 12.66, and above the 200-day MA of 9.31, indicating a neutral trend. The MACD of 0.55 indicates Positive momentum. The RSI at 45.80 is Neutral, neither overbought nor oversold. The STOCH value of 10.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CGEM.

Cullinan Management Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CGEM	59 Neutral	$816.50M	-2.78	-46.19%	―	―	-27.86%
RNTX	53 Neutral	$34.17M	-1.36	-217.16%	―	―	15.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NEUP	48 Neutral	$24.47M	2.36	-1538.29%	―	―	―

Cullinan Management Corporate Events

Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook

On January 8, 2026, Cullinan Therapeutics issued a corporate update outlining a catalyst-heavy 2026 centered on its T cell engager pipeline in immunology and oncology, alongside a solid balance sheet. In immunology, CLN-978 continues Phase 1 development across rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s disease in the OUTRACE program, with completed lower-dose cohorts showing no dose-limiting toxicities and multiple clinical data readouts planned throughout 2026 that could establish Cullinan as an early mover in CD19 T cell engagers for autoimmune disease. The company is also advancing velinotamig for autoimmune indications via a Phase 1 study initiated in China by partner Genrix in December 2025, with data expected in late 2026 to inform global development. In oncology, CLN-049 for relapsed/refractory acute myeloid leukemia, which received U.S. FDA Fast Track designation in December 2025 after compelling data presented at ASH 2025, is slated for a series of key milestones in 2026 including initiation of monotherapy expansion cohorts, completion of enrollment to determine a Phase 2 dose for a planned pivotal trial, and launch of a frontline combination study. Meanwhile, partner Taiho is progressing zipalertinib for EGFR exon 20 insertion–mutant non-small cell lung cancer, with a rolling U.S. NDA for relapsed disease expected to finish in the first quarter of 2026 and full enrollment of the frontline REZILIENT3 trial targeted for the first half of 2026, positioning Cullinan to benefit from up to $130 million in U.S. regulatory milestones and a 50/50 U.S. profit share. The company reported unaudited preliminary cash and investments of $439 million as of December 31, 2025, providing runway into 2029 under its current plan, which supports an aggressive clinical agenda that could materially strengthen its competitive position in both autoimmune and oncology markets if the upcoming data and regulatory events break favorably.

The most recent analyst rating on (CGEM) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Cullinan Management stock, see the CGEM Stock Forecast page.